Skip to main content
. 2022 Oct 28;101(43):e30975. doi: 10.1097/MD.0000000000030975

Table 3.

Mortality (n = 15) and infections (n = 41).

Event N (%)
Cause of death Refractory respiratory failure 7/15 (46.6)
Cerebrovascular event 1/15 (6.6)
Cardiovascular event 1/15 (6.6)
Sepsis with septic shock 6/15 (40)
Infections Secondary bacterial infections 8/41 (19.5)
Mucormycosis 2/41 (4.8)
Aspergillosis 3/41 (7.3)
>1 infection 5/41 (12.2)
Adverse events attributed to tofacitinib Pulmonary thrombosis 1/41 (2.4)